Avanos Medical Inc. (AVNS) stock plummeted more than 10% in the pre-market trading session on Wednesday, following the release of the company's disappointing fourth-quarter results and underwhelming guidance for the full year.
The medical technology company reported a staggering net loss of $397.3 million for the fourth quarter, with an operating loss of $418.5 million and an EBITDA loss of $407.6 million. Despite generating $179.6 million in sales, Avanos Medical's gross profit stood at a mere $98 million, reflecting the company's significant operational challenges.
Adding to the concerns, Avanos Medical provided a lackluster earnings guidance for the full year, projecting an adjusted EPS range of $1.05 to $1.25, significantly lower than market expectations. The company's weak outlook further exacerbated investors' concerns about its future prospects, contributing to the pre-market sell-off.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。